/

ALLO

Allogene Therapeutics, Inc.Closed

1.29−0.11 −7.86%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.30 +0.78%

Open

1.39

Prev close

1.40

Day range

1.301.40

52-week range

1.044.46

Volume

6.42M1.14×

Mkt cap

445.68M

P/E ttm

—

Fwd P/E

-2.09

EPS ttm

-0.6600

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−71.08%

Price Chart

Yahoo Finance · delayed

ALLOOct 12, 2026O 1.45H 1.46L 1.39C 1.40−0.06 (−4.11%)Vol 4.31M

SMA 501.83
SMA 2001.99

1Y change +13.82% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ALLO Allogene Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.67%
1 month: −21.35%
3 months: −27.46%
6 months: −54.25%
Year to date: +2.19%
1 year: +13.82%

Valuation & ownership

Market cap: 445.68M
Enterprise value: 192.09M
P/E (ttm): —
Forward P/E: -2.09
PEG ratio: —
Price / book: 1.02
Price / sales (ttm): 96.05
EV / EBITDA: -1.14
EPS (ttm): -0.6600
EPS (forward): -0.6171
Beta (5y monthly): 0.56
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 345.49M
Float: 281.13M
Short % of float: 17.81%
Short ratio (days): 9.71
Held by insiders: 11.03%
Held by institutions: 82.62%
Avg volume (3m): 5.64M
50-day average: 1.83
200-day average: 1.99
52-week change: +13.82%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 26.5
vs 50-day SMA: −23.46%
vs 200-day SMA: −29.78%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.07%
Realised vol (20d, ann.): 32.9%
From 52-week high: −68.61%
From 52-week low: +34.62%

ANR

Analyst Consensus

9 analysts

Consensus

—

Mean target

9.00

+597.67% implied

Low 4.00Median 9.00High 14.00

Recommendation trend

Now11 / 1 / 0
1m ago11 / 1 / 0

DES

About Allogene Therapeutics, Inc.

Yahoo Finance profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 150
Headquarters: South San Francisco, CA, United States
Website: allogene.com
Officers: Dr. Arie S. Belldegrun F.A.C.S., M.D. Co-Founder & Executive Chairman
Dr. Zachary J. Roberts M.D., Ph.D. President, CEO & Director

SEAS

Seasonality · ALLO

2018–2026 · monthly returns

Strongest month Feb +5.54%Weakest month Mar −13.11%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	34.3	51.1	-12.2	-12.7	1.9	-4.1	-9.6	6.4	-20.0	-19.4			−5.8%
2025	-15.5	8.3	-25.1	15.1	-30.4	-3.4	8.8	-8.1	9.7	0.0	17.7	-6.2	−35.7%
2024	9.7	39.5	-9.0	-38.3	-9.4	-6.8	26.2	-10.5	6.5	-8.6	-3.1	-14.1	−33.6%
2023	22.7	-17.7	-22.2	9.9	-3.3	-5.3	-0.2	-21.6	-18.5	-11.0	-16.7	36.6	−49.0%
2022	-23.3	-20.1	-0.4	-8.3	-5.0	43.8	13.9	5.6	-21.2	-4.6	-4.3	-36.2	−57.8%
2021	37.5	0.0	1.7	-12.4	-16.9	1.5	-15.8	8.7	7.8	-32.9	7.3	-19.3	−40.9%
2020	-16.4	24.3	-28.0	48.7	66.6	-11.1	-14.4	-2.8	5.8	-10.1	-8.5	-18.7	−2.8%
2019	12.6	4.5	-8.8	3.6	-12.4	2.4	15.5	-12.2	0.1	5.6	-2.2	-7.8	−3.5%
2018											30.3	-13.9	+12.2%

INSD

Insider Activity · ALLO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

47.7K shares

Sells, 6 months

39.3K shares

Net shares

+8.4K

Net change in insider shares

0.00%

Date	Insider	Transaction	Shares	Value
Aug 20, 2026	Douglas Earl MartinGeneral Counsel	Sale at price 2.12 per share.	29.7K	$62.96K
Jun 17, 2026	Kazam Joshua ADirector	—	47.7K	—
Apr 20, 2026	Yoshiyama AnnieOfficer	Sale at price 2.31 per share.	9.6K	$22.14K
Mar 30, 2026	Beneski Benjamin MachinasChief Technology Officer	Sale at price 2.50 per share.	2.9K	$7.17K
Mar 15, 2026	Chang David DChief Executive Officer	Sale at price 2.47 per share.	47.8K	$117.97K
Mar 15, 2026	Beneski Benjamin MachinasChief Technology Officer	Sale at price 2.47 per share.	4.8K	$11.94K
Mar 1, 2026	Beneski Benjamin MachinasChief Technology Officer	Sale at price 2.60 per share.	7.1K	$18.54K
Feb 1, 2026	Douglas Earl MartinGeneral Counsel	Sale at price 1.76 per share.	22.9K	$40.30K
Feb 1, 2026	Chang David DChief Executive Officer	Sale at price 1.80 per share.	95.3K	$171.48K
Feb 1, 2026	Parker Geoffrey MChief Financial Officer	Sale at price 1.76 per share.	24K	$42.24K
Feb 1, 2026	Yoshiyama AnnieOfficer	Sale at price 1.72 per share.	4.2K	$7.17K
Feb 1, 2026	Roberts ZacharyOfficer	Sale at price 1.77 per share.	35.7K	$63.19K
Feb 1, 2026	Beneski Benjamin MachinasChief Technology Officer	Sale at price 1.73 per share.	7.5K	$13.06K
Jan 20, 2026	Roberts ZacharyOfficer	Sale at price 1.56 per share.	26.3K	$40.98K
Dec 17, 2025	Kazam Joshua ADirector	—	47.7K	—
Nov 16, 2025	Beneski Benjamin MachinasChief Technology Officer	Sale at price 1.22 per share.	786	$959
Oct 20, 2025	Parker Geoffrey MChief Financial Officer	Sale at price 1.26 per share.	36.7K	$46.17K
Jun 9, 2025	Messemer Deborah MDirector	Sale at price 1.42 per share.	36.9K	$52.38K
Apr 20, 2025	Yoshiyama AnnieOfficer	Sale at price 1.41 per share.	9.6K	$13.54K
Mar 13, 2025	Chang David DChief Executive Officer	Sale at price 1.96 per share.	46.7K	$91.47K

13F

Investors Holding ALLO

latest 13F filings of 29 followed managers

Investors holding ALLO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.0M	0.01%	3.83M	+79%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ALLO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ALLO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Allogene Therapeutics, Inc.

Seasonality · ALLO

Insider Activity · ALLO

Congress Trades · ALLO

Investors Holding ALLO

Investors Holding ALLO

Congress Trades · ALLO

Insider Activity · ALLO

Seasonality · ALLO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Allogene Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News